Epigral Ltd

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 September 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating. Despite recent headwinds reflected in its share price decline, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value within a challenging market environment.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 August 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Epigral Ltd, a small-cap player in the specialty chemicals sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade. This change reflects evolving market perceptions amid a backdrop of mixed financial metrics and sector-wide valuation disparities. Investors are now reassessing the company’s price attractiveness relative to its historical averages and peer group, prompting a deeper analysis of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios alongside operational returns and market performance.

Epigral Ltd, a specialty chemicals small-cap, has exhibited a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish trend. Despite a recent day gain of 3.88%, the stock’s technical indicators present a complex picture, with some signals suggesting cautious optimism while others maintain a bearish outlook. This article analyses the latest technical parameters, including MACD, RSI, moving averages, and other momentum indicators, to provide a comprehensive view of Epigral’s current market positioning.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 August 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Epigral Ltd, a specialty chemicals small-cap, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend despite some mildly bullish weekly signals. The stock’s recent price action and technical parameters suggest caution for investors as the company navigates a challenging market environment.

Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has exhibited a nuanced shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a modest day change of 0.22% to close at ₹1,100.80, the stock’s technical indicators reveal a complex interplay of bullish and bearish signals, reflecting cautious investor sentiment amid broader market volatility.

Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a modest recovery over the past month, the stock’s overall trajectory remains under pressure, reflecting challenges in sustaining upward momentum amid broader market dynamics.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 August 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has exhibited a nuanced shift in its technical momentum, moving from a bearish stance to a mildly bearish trend. Despite a recent day gain of 2.59%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators, reflecting cautious investor sentiment amid broader market challenges.

Epigral Ltd, a small-cap player in the specialty chemicals sector, has experienced a notable shift in its technical momentum, signalling increased bearish pressure. Despite a modest recovery in monthly MACD readings, the overall technical landscape remains challenging, with key indicators such as moving averages and KST pointing to sustained downward trends. This analysis delves into the recent technical parameter changes, price momentum, and comparative performance against the Sensex to provide a comprehensive view for investors.

Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has witnessed a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change reflects evolving market perceptions amid sector-wide valuation disparities and company-specific performance metrics, prompting investors to reassess the stock’s price attractiveness relative to its peers and historical benchmarks.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 28 July 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has reported a stabilisation in its financial trend for the quarter ended June 2026, shifting from a negative trajectory to a flat performance. Despite some encouraging signs in operating profit and quarterly earnings growth, the company continues to face challenges in return on capital and cash reserves, reflecting a mixed outlook for investors.

Epigral Ltd., a specialty chemicals manufacturer with a market capitalisation of ₹5,088 crores, reported a mixed performance in Q1 FY27, with consolidated net profit rising 23.21% quarter-on-quarter to ₹99.74 crores despite a 4.18% decline in net sales. The company's shares traded at ₹1,159.75 on July 27, down 37.28% over the past year, significantly underperforming the broader Sensex and the specialty chemicals sector.